PPARGC1A and Disorder of lipid metabolism: et Zucc., can activate the activities of ABCA1, ABCG1, and ApoE with PGC-1α as the central target to inhibit lipid deposition in cells and improve lipid metabolism disorder in the kidney, thus preventing or delaying the occurrence and development of DN (Figure 8).